MapLight Therapeutics (MPLT) Research & Development (2024 - 2025)
MapLight Therapeutics recorded quarterly Research & Development of $64.6 million in Q4 2025, up 138.51% quarter-over-quarter from $27.1 million in Q3 2025, and up 211.99% year-over-year from $20.7 million in Q4 2024.
MapLight Therapeutics' Research & Development history runs 2 years deep, the most recent figure standing at $64.6 million for Q4 2025.
- In Q4 2025, Research & Development rose 211.99% year-over-year to $64.6 million; the TTM figure through Dec 2025 stood at $129.2 million (changed N/A YoY), while the FY2025 annual figure was $138.3 million, up 101.9% from the prior year.
- Research & Development came in at $64.6 million for Q4 2025 at MapLight Therapeutics, up from $27.1 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $64.6 million in Q4 2025 to a low of $16.8 million in Q3 2024.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 626,092.00 |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | 4.32 Mn |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | -101.30 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 1.46 Mn |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 961.60 Mn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | -2.30 Mn |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 1.54 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 364.87 Mn |
| 10 | MapLight Therapeutics | 254.43 Mn | 254.43 Mn | - | 64.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 64.62 Mn |
| Sep 30, 2025 | 27.09 Mn |
| Dec 31, 2024 | 20.71 Mn |
| Sep 30, 2024 | 16.81 Mn |